• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多支冠状动脉疾病患者的血运重建策略与生存。

Revascularization Strategies and Survival in Patients With Multivessel Coronary Artery Disease.

机构信息

Leviev Heart Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Division of Cardiology, Rambam Healthcare Center, Haifa, Israel.

出版信息

Ann Thorac Surg. 2019 Jan;107(1):106-111. doi: 10.1016/j.athoracsur.2018.07.070. Epub 2018 Sep 26.

DOI:10.1016/j.athoracsur.2018.07.070
PMID:30267693
Abstract

BACKGROUND

We sought to assess real-world implementation of the guidelines in patients with multivessel coronary artery disease (CAD) using a prospective national registry in Israel.

METHODS

All consecutive patients with left main or 2- to 3-vessel CAD involving the proximal or mid left anterior descending artery were enrolled in a dedicated multicenter registry. Patients were managed at the discretion of the treating team at each hospital and were followed for 30 months.

RESULTS

This registry included 1,064 patients, 55% treated with percutaneous coronary intervention (PCI) and 45% with coronary artery bypass surgery (CABG). Multivariate logistic regression analysis showed that chronic renal failure (odds ratio [OR], 2.43; p = 0.001) and prior myocardial infarction (OR, 1.7; p = 0.024) were associated with referral to PCI versus CABG, whereas male gender (OR, 2.27; p < 0.001), prior aspirin treatment (OR, 1.72; p = 0.005), diabetes mellitus (OR, 1.51; p = 0.007), 3-vessel CAD (OR, 3.45; p < 0.001) and SYNTAX score (SS) greater than 32 (OR, 10.0; p < 0.001) were associated with referral to CABG versus PCI. Each point increment in the SS was independently associated with a 9% greater likelihood of referral to CABG (p < 0.001). Survival analysis showed that mortality risk was lower among PCI patients less than 8 months after the procedure, and CABG was associated with a significant survival benefit thereafter.

CONCLUSIONS

We found good agreement with current guidelines regarding revascularization strategies in real-world patients with multivessel CAD. The SS was the main independent predictor associated with the choice of revascularization strategy. The time-dependent association between revascularization strategy and long-term survival should be incorporated in the risk assessment of this population.

摘要

背景

我们旨在通过以色列一项前瞻性全国登记处,评估多血管冠状动脉疾病(CAD)患者指南的实际实施情况。

方法

所有左主干或 2-3 支血管 CAD 累及近端或中段前降支的连续患者均纳入专门的多中心登记处。患者由每家医院的治疗团队根据病情进行治疗,并随访 30 个月。

结果

该登记处纳入了 1064 例患者,55%接受经皮冠状动脉介入治疗(PCI),45%接受冠状动脉旁路移植术(CABG)。多变量逻辑回归分析显示,慢性肾功能衰竭(比值比[OR],2.43;p=0.001)和既往心肌梗死(OR,1.7;p=0.024)与 PCI 与 CABG 治疗相关,而男性(OR,2.27;p<0.001)、既往阿司匹林治疗(OR,1.72;p=0.005)、糖尿病(OR,1.51;p=0.007)、3 支血管 CAD(OR,3.45;p<0.001)和 SYNTAX 评分(SS)大于 32(OR,10.0;p<0.001)与 CABG 与 PCI 治疗相关。SS 每增加 1 分,与 CABG 治疗的可能性增加 9%相关(p<0.001)。生存分析显示,PCI 患者在术后 8 个月内死亡率较低,此后 CABG 具有显著的生存获益。

结论

我们发现,多血管 CAD 实际患者的血运重建策略与当前指南一致。SS 是与血运重建策略选择相关的主要独立预测因素。血运重建策略与长期生存之间的时间相关性应纳入该人群的风险评估中。

相似文献

1
Revascularization Strategies and Survival in Patients With Multivessel Coronary Artery Disease.多支冠状动脉疾病患者的血运重建策略与生存。
Ann Thorac Surg. 2019 Jan;107(1):106-111. doi: 10.1016/j.athoracsur.2018.07.070. Epub 2018 Sep 26.
2
Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG).伴有非ST段抬高型心肌梗死的糖尿病合并多支冠状动脉疾病患者的血运重建趋势:来自国家心血管数据注册库急性冠状动脉治疗和干预结果网络注册库-遵循指南行动(NCDR ACTION注册库-GWTG)的见解
Circ Cardiovasc Qual Outcomes. 2016 May;9(3):197-205. doi: 10.1161/CIRCOUTCOMES.115.002084. Epub 2016 May 10.
3
Real-life characteristics and outcomes of patients who undergo percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease: data from the prospective Multi-vessel Coronary Artery Disease (MULTICAD) Israeli Registry.接受经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干冠状动脉疾病患者的真实生活特征和结局:来自前瞻性多支冠状动脉疾病(MULTICAD)以色列注册研究的数据。
Eur J Cardiothorac Surg. 2018 Oct 1;54(4):717-723. doi: 10.1093/ejcts/ezy115.
4
Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.冠状动脉旁路移植术与药物洗脱支架置入术治疗左主干或多支冠状动脉疾病:一项个体患者数据的荟萃分析。
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008.
5
Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.当前杂交血运重建的现状:来自 NCDR CathPCI 注册研究的报告。
Am Heart J. 2019 Sep;215:167-177. doi: 10.1016/j.ahj.2019.06.014. Epub 2019 Jun 28.
6
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2).经皮冠状动脉介入治疗与冠状动脉旁路移植术在需要透析的终末期肾病患者中的比较(CREDO-Kyoto PCI/CABG 登记研究队列-2 的 5 年结果)。
Am J Cardiol. 2014 Aug 15;114(4):555-61. doi: 10.1016/j.amjcard.2014.05.034. Epub 2014 Jun 6.
7
Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review.冠状动脉旁路移植术与经皮冠状动脉介入治疗在冠状动脉血运重建中的比较:一项系统评价。
JAMA. 2013 Nov 20;310(19):2086-95. doi: 10.1001/jama.2013.281718.
8
The Clinical SYNTAX score predicts survival better than the SYNTAX score in coronary revascularization.在冠状动脉血运重建中,临床SYNTAX评分比SYNTAX评分更能预测生存率。
J Thorac Cardiovasc Surg. 2024 Jan;167(1):164-173.e4. doi: 10.1016/j.jtcvs.2022.02.030. Epub 2022 Feb 24.
9
The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease.Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study:5 年随访:多血管病变糖尿病患者经皮冠状动脉介入治疗与冠状动脉旁路移植术血运重建的比较。
J Cardiovasc Med (Hagerstown). 2010 Jan;11(1):26-33. doi: 10.2459/JCM.0b013e328330ea32.
10
Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.糖尿病患者急性冠脉综合征的管理:FREEDOM 试验的启示。
Clin Ther. 2013 Aug;35(8):1069-75. doi: 10.1016/j.clinthera.2013.07.427.

引用本文的文献

1
Gender related outcome differences in off-pump coronary artery bypass grafting.非体外循环冠状动脉旁路移植术中与性别相关的结果差异。
Front Cardiovasc Med. 2025 Aug 1;12:1641784. doi: 10.3389/fcvm.2025.1641784. eCollection 2025.
2
Revascularization strategies for multivessel coronary artery disease based on sex and age.基于性别和年龄的多支冠状动脉疾病血运重建策略。
Eur J Cardiothorac Surg. 2023 Nov 1;64(5). doi: 10.1093/ejcts/ezad374.
3
Sex differences in coronary artery bypass graft surgery outcomes: a narrative review.冠状动脉搭桥手术结果中的性别差异:一项叙述性综述。
J Thorac Dis. 2023 Sep 28;15(9):5041-5054. doi: 10.21037/jtd-23-294. Epub 2023 Aug 16.
4
Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7.经皮冠状动脉介入治疗和手术干预治疗冠心病的性别结局:JACC 焦点研讨会 3/7。
J Am Coll Cardiol. 2022 Apr 12;79(14):1407-1425. doi: 10.1016/j.jacc.2021.07.066.
5
Clinical Characteristics and Short-Term Outcomes of Patients Presenting with Acute Myocardial Infarction having Multi-vessel disease - A Single Middle- eastern Tertiary-Care Center Experience.多支血管病变的急性心肌梗死患者的临床特征和短期预后 - 单一中东三级医疗中心的经验。
Indian Heart J. 2022 Jan-Feb;74(1):28-33. doi: 10.1016/j.ihj.2021.11.184. Epub 2021 Dec 2.
6
Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model.非体外循环冠状动脉旁路移植术后严重出血:预测因素及风险模型
J Geriatr Cardiol. 2021 Jun 28;18(6):449-461. doi: 10.11909/j.issn.1671-5411.2021.06.006.
7
Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery.2 型糖尿病对冠状动脉旁路手术后短期和长期死亡率的影响。
Cardiovasc Diabetol. 2018 Nov 29;17(1):151. doi: 10.1186/s12933-018-0796-7.